Use of hepatitis B virus DNA quantitation to predict hepatitis B e antigen reversion in cases of chronic hepatitis B.
Seventy-three chronic hepatitis B patients who had either hepatitis B e antigen (HBeAg) seroconversion (group I) or HBeAg-negative disease (group II) were studied. HBV DNA levels at HBeAg seroconversion (group I) and at initial visits (group II) were significantly lower among patients who were persistently negative for HBeAg than among those who underwent HBeAg reversion.
Chan
Henry Lik-Yuen
HL
Department of Medicine and Therapeutics, Chinese University of Hong Kong, Hong Kong SAR, China. hlychan@cuhk.edu.hk
Wong
May Ling
ML
Hui
Alex Yui
AY
Hung
Lawrence Cheung-Tsui
LC
Chan
Francis Ka-Leung
FK
Sung
Joseph Jao-Yiu
JJ
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D004279:DNA, Viral / Q000097:blood*; D005260:Female; D006510:Hepatitis B Antibodies / Q000097:blood*; D006513:Hepatitis B e Antigens / Q000032:analysis* / Q000276:immunology; D006515:Hepatitis B virus / Q000276:immunology / Q000302:isolation & purification; D019694:Hepatitis B, Chronic / Q000821:virology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D012074:Remission Induction; D019562:Viral Load
D004279:DNA, Viral; D006510:Hepatitis B Antibodies; D006513:Hepatitis B e Antigens